NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 120 filers reported holding NURIX THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,465,098 | -19.1% | 440,852 | +2.8% | 0.00% | 0.0% |
| Q2 2023 | $4,282,133 | +20.6% | 428,642 | +7.2% | 0.00% | 0.0% |
| Q1 2023 | $3,552,159 | -20.7% | 400,018 | -1.9% | 0.00% | 0.0% |
| Q4 2022 | $4,479,214 | -14.9% | 407,943 | +1.0% | 0.00% | 0.0% |
| Q3 2022 | $5,262,000 | +7.0% | 403,742 | +4.0% | 0.00% | 0.0% |
| Q2 2022 | $4,919,000 | +15.3% | 388,194 | +27.5% | 0.00% | 0.0% |
| Q1 2022 | $4,266,000 | -53.4% | 304,537 | -3.6% | 0.00% | 0.0% |
| Q4 2021 | $9,149,000 | -4.9% | 316,021 | -1.6% | 0.00% | -50.0% |
| Q3 2021 | $9,618,000 | +22.1% | 321,006 | +8.1% | 0.00% | +100.0% |
| Q2 2021 | $7,877,000 | +8.9% | 296,890 | +27.6% | 0.00% | 0.0% |
| Q1 2021 | $7,234,000 | +59.7% | 232,677 | +68.8% | 0.00% | 0.0% |
| Q4 2020 | $4,531,000 | -2.6% | 137,812 | +3.4% | 0.00% | 0.0% |
| Q3 2020 | $4,654,000 | – | 133,338 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |